Skip to main
OMCL

Omnicell (OMCL) Stock Forecast & Price Target

Omnicell (OMCL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Omnicell is expected to continue seeing strong demand in the healthcare industry as more providers look to streamline medication management and reduce administrative tasks. This will likely translate into strong revenue and earnings growth for the company in the coming years. Additionally, the recent launch of Titan XT and Omnisphere platforms bodes well for the company's future prospects. Furthermore, the company's solid execution, new customer acquisitions and increasing market share also add to its positive outlook.

Bears say

Omnicell is facing several key challenges that could negatively impact its revenue and earnings, including the potential for economic recession and decreased demand for its products due to weak economic conditions. Additionally, the company's reliance on hosting and sharing sensitive patient data leaves it vulnerable to cybersecurity breaches, which could have a significant impact on its financial results. Furthermore, as the company shifts towards offering more products and services on a subscription basis, it will require a significant investment of resources, and any delays or challenges in this transition could negatively affect revenue recognition. Given these risks, as well as potential regulatory challenges, the financial analyst maintains a negative outlook on Omnicell's stock.

Omnicell (OMCL) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omnicell and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omnicell (OMCL) Forecast

Analysts have given Omnicell (OMCL) a Buy based on their latest research and market trends.

According to 5 analysts, Omnicell (OMCL) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omnicell (OMCL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.